Trial Profile
A real world study evaluating and comparing long-term efficacy and safety of etrombopag and romiplostim in adult patients with chronic immune thrombocytopenia in clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2017
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 24 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association